HC Wainwright & Co. Maintains Buy on Zymeworks, Raises Price Target to $51

Zymeworks Inc.

Zymeworks Inc.

ZYME

0.00

HC Wainwright & Co. analyst Robert Burns maintains Zymeworks (NASDAQ: ZYME) with a Buy and raises the price target from $46 to $51.